💊
Hympavzi
marstacimab
Hémophilie A ; Hémophilie B
✅ Autorisé
✅
Aucune alerte active
Ce médicament ne fait l'objet ni de pénuries en cours, ni de lettres de sécurité, ni de rappels.
À quoi ça sert
Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: Haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have severe disease (FVIII < 1%) with factor VIII inhibitors Haemophilia B (congenital factor IX deficiency) without factor IX inhibitors who have severe disease (FIX < 1%) with factor IX inhibitors.
⚠️ Sécurité des patients
No
Page officielle de l'EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/hympavzi